[go: up one dir, main page]

ATE291430T1 - Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen - Google Patents

Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen

Info

Publication number
ATE291430T1
ATE291430T1 AT98960277T AT98960277T ATE291430T1 AT E291430 T1 ATE291430 T1 AT E291430T1 AT 98960277 T AT98960277 T AT 98960277T AT 98960277 T AT98960277 T AT 98960277T AT E291430 T1 ATE291430 T1 AT E291430T1
Authority
AT
Austria
Prior art keywords
estrogen
treatment
present
lowest doses
postclimacteric women
Prior art date
Application number
AT98960277T
Other languages
English (en)
Inventor
Steven Cummings
Herman Ellman
Bruce Ettinger
Original Assignee
Univ California
Kaiser Foundation Health Plan
Permanente Medical Group Inc
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291430(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Kaiser Foundation Health Plan, Permanente Medical Group Inc, Berlex Lab filed Critical Univ California
Application granted granted Critical
Publication of ATE291430T1 publication Critical patent/ATE291430T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT98960277T 1997-11-21 1998-11-19 Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen ATE291430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (1)

Publication Number Publication Date
ATE291430T1 true ATE291430T1 (de) 2005-04-15

Family

ID=25523181

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98960277T ATE291430T1 (de) 1997-11-21 1998-11-19 Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen
AT05006108T ATE383862T1 (de) 1997-11-21 1998-11-19 Transdermale behandlung postklimakterischer frauen mit ultra-niedrigen estrogendosen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05006108T ATE383862T1 (de) 1997-11-21 1998-11-19 Transdermale behandlung postklimakterischer frauen mit ultra-niedrigen estrogendosen

Country Status (26)

Country Link
US (1) US5891868A (de)
EP (2) EP1032398B1 (de)
JP (2) JP2001523722A (de)
KR (1) KR100576568B1 (de)
CN (1) CN100398110C (de)
AT (2) ATE291430T1 (de)
AU (1) AU760108B2 (de)
BR (1) BR9814984A (de)
CA (1) CA2306881C (de)
CL (1) CL2004001852A1 (de)
CZ (1) CZ299226B6 (de)
DE (2) DE69829501T2 (de)
EA (1) EA004573B1 (de)
EE (1) EE04221B1 (de)
ES (2) ES2299912T3 (de)
HK (1) HK1082919A1 (de)
HU (1) HUP0004339A3 (de)
IL (1) IL136175A (de)
IS (1) IS2132B (de)
NO (1) NO326929B1 (de)
NZ (1) NZ504668A (de)
PL (1) PL193897B1 (de)
PT (1) PT1032398E (de)
SK (1) SK284971B6 (de)
TR (1) TR200001460T2 (de)
WO (1) WO1999026631A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
ES2267707T3 (es) * 2000-01-14 2007-03-16 Sterix Limited Composiciones farmaceuticas que contienen estructuras esteroides y su utilizacion.
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DK1334367T3 (da) * 2000-10-13 2006-10-09 Abbott Lab Metode til bestemmelse af startdosis for vitamin-D-forbindelser
IL158871A0 (en) 2001-07-31 2004-05-12 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2005011618A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Methods for the treatment of male and female sexual dysfunction
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
EP1971325A2 (de) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Konjugierte östrogen-zusammensetzungen, applikatoren, kits und verfahren zur ihrer herstellung und verwendung
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
JP5687901B2 (ja) * 2007-10-15 2015-03-25 アルザ・コーポレーシヨン 日に１回の取り替えによるフェンタニルの経皮投与
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
WO2011128337A2 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Low-dosed solid oral dosage forms for hrt
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20160055934A (ko) * 2013-10-07 2016-05-18 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
CZ299226B6 (cs) 2008-05-21
EP1032398A1 (de) 2000-09-06
JP2001523722A (ja) 2001-11-27
EP1570848A1 (de) 2005-09-07
EP1570848B1 (de) 2008-01-16
NO326929B1 (no) 2009-03-16
CN100398110C (zh) 2008-07-02
SK284971B6 (sk) 2006-03-02
KR100576568B1 (ko) 2006-05-08
DE69839026T2 (de) 2009-01-08
PL193897B1 (pl) 2007-03-30
EE04221B1 (et) 2004-02-16
EA004573B1 (ru) 2004-06-24
ES2299912T3 (es) 2008-06-01
ES2241188T3 (es) 2005-10-16
IS2132B (is) 2006-08-15
WO1999026631A1 (en) 1999-06-03
CL2004001852A1 (es) 2005-06-03
TR200001460T2 (tr) 2000-11-21
DE69829501T2 (de) 2006-01-26
US5891868A (en) 1999-04-06
PL341112A1 (en) 2001-03-26
CN1279611A (zh) 2001-01-10
IS5468A (is) 2000-04-26
DE69839026D1 (de) 2008-03-06
AU760108B2 (en) 2003-05-08
EA200000563A1 (ru) 2001-08-27
JP2004083599A (ja) 2004-03-18
CA2306881A1 (en) 1999-06-03
ATE383862T1 (de) 2008-02-15
HK1082919A1 (en) 2006-06-23
HUP0004339A2 (hu) 2001-05-28
NO20002587L (no) 2000-07-19
NO20002587D0 (no) 2000-05-19
KR20010032257A (ko) 2001-04-16
EE200000307A (et) 2001-10-15
DE69829501D1 (de) 2005-04-28
CZ20001602A3 (cs) 2001-02-14
EP1032398B1 (de) 2005-03-23
IL136175A (en) 2005-11-20
HUP0004339A3 (en) 2001-09-28
SK7332000A3 (en) 2001-03-12
CA2306881C (en) 2008-09-02
PT1032398E (pt) 2005-08-31
AU1591499A (en) 1999-06-15
NZ504668A (en) 2002-11-26
IL136175A0 (en) 2001-05-20
BR9814984A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE291430T1 (de) Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen
ATE235191T1 (de) Markraumnagel für die versorgung von frakturen der hüfte
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE59812897D1 (de) Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen
EP0961613A4 (de) Methoden und zusammenstellungen zur behandlung von stoerungen der knochenresorption, u.a. osteoporose
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE69941280D1 (de) Vorrichtung zur Behandlung von Stenosen an Verzweigungen
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
MXPA02001204A (es) Compuestos calciliticos.
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DE60219761D1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
TR199900504T2 (xx) Osteoporoz dahil olmak �zere menopoz sonras� hastal�klar�n tedavi y�ntemi
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
DE60032621D1 (de) Die verwendung von estrogen-verbindungen zur behandlung von osteoporose
DE60001945T2 (de) Neuartige bispidin-derivate, die sich zur behandlung von herzrhythmusstörungen eignen
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
RU95100742A (ru) Способ удлинения костей
ATA144696A (de) Vorrichtung zur behandlung von schenkenhalsfrakturen
IT1276508B1 (it) Plantare ortopedico a stimolazione variabile.
IT8809441A0 (it) Macchina cilindratrice per il trattamento di cuoio, pelli ed altro escludendo la generazione di scarti ai bordi
UA32147A (uk) Спосіб профілактики вторинних деформацій носа при вроджених та набутих незрощеннях верхньої губи

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032398

Country of ref document: EP